The druggability of intracellular nucleotide-degrading enzymes Chiara RampazzoMaria Grazia TozziLars Petter Jordheim Review Article 27 November 2015 Pages: 883 - 893
The selective estrogen receptor modulators in breast cancer prevention Fangxuan LiJinli DouJuntian Liu Review Article 20 January 2016 Pages: 895 - 903
Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes Jingya ZhangLinna ZhangGuisen Zhao Review Article 18 January 2016 Pages: 905 - 926
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data Thierry WendlingHitesh MistryLeon Aarons Original Article Open access 03 March 2016 Pages: 927 - 938
Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy Ales GroseljMojca KrzanMaja Cemazar Original Article 18 March 2016 Pages: 939 - 947
A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer E. KontopodisA. KotsakisS. Agelaki Original Article 19 March 2016 Pages: 949 - 956
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer Hiromi KataokaYoshinori MoriTakashi Joh Original Article 22 March 2016 Pages: 957 - 962
Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation Fei ZhaoJia MingLinjun Fan Original Article 24 March 2016 Pages: 963 - 972
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers Muhammad R. KhawajaAlpa M. NickAung Naing Original Article 24 March 2016 Pages: 973 - 977
Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Young Saing KimIn Gyu HwangJoon Oh Park Original Article 26 March 2016 Pages: 979 - 985
Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors Satoshi YoshibaMendel JansenJeanne Mendell Original Article 26 March 2016 Pages: 987 - 996
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors Toshio ShimizuKazuya FukuokaKazuhiko Nakagawa Original Article Open access 30 March 2016 Pages: 997 - 1003
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience Kenichiro KudoKatsuyuki HottaKatsuyuki Kiura Original Article 31 March 2016 Pages: 1005 - 1009
Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer Masato KarayamaNaoki InuiTakafumi Suda Original Article 31 March 2016 Pages: 1011 - 1018
Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor Masahito OgasawaraYutaka NakamuraYutaka Takaoka Original Article 04 April 2016 Pages: 1019 - 1029
Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer Yuichi OzawaDaisuke AkahoriTakafumi Suda Original Article 05 April 2016 Pages: 1031 - 1038
Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice Andrea N. EdgintonEric I. ZimmermanJohn C. Panetta Original Article 06 April 2016 Pages: 1039 - 1052
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy Neta GoldschmidtGeffen KleinsternMoshe E Gatt Original Article 07 April 2016 Pages: 1053 - 1060
Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer Chao ShangYan GuoBaojun Huang Original Article 07 April 2016 Pages: 1061 - 1067
Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer Fadi FarhatJoseph G. KattanMarwan Ghosn Original Article 08 April 2016 Pages: 1069 - 1077
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle Howard A. BurrisJeffrey R. InfanteSuzanne F. Jones Original Article 09 April 2016 Pages: 1079 - 1086
The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells Fei ShangMingming LiuRuijuan Xiu Original Article 12 April 2016 Pages: 1087 - 1096
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer Rabih SaidEugenia KakadiarisApostolia M. Tsimberidou Original Article 16 April 2016 Pages: 1097 - 1102